Navigation Links
Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds
Date:12/12/2011

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.

Jakubowiak will present final results of the phase I-II study on Dec. 12, 2011, at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif. The initial results from phase I of this study were presented at the ASH Meeting 2010 and were selected for the Best of ASH 2010 session.

The combination includes an investigational medicine called carfilzomib combined with two standard medications: lenalidomide, an analogue of thalidomide, and low-dose dexamethasone, an anti-inflammatory with anti-cancer properties.

"This combination appears to deliver everything we expected and more," said Jakubowiak, who came to the University of Chicago this fall from the University of Michigan. "We have seen excellent efficacy — the best reported to date — without the neurotoxicity that has been problematic with other drug combinations."

Multiple myeloma is a type of cancer that arises in plasma cells, the bone marrow component that produces antibodies. The American Cancer Society estimates that about 20,520 Americans will be diagnosed with multiple myeloma in 2011 and 10,610 will die from the disease.

The research team enrolled 53 people at three different carfilzomib dose levels. Most patients responded quickly t
'/>"/>

SOURCE University of Chicago Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
2. Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
4. Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
6. New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1
7. Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
8. FDA Approves Combination Therapy Juvisync
9. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
10. Interim Data Announced for BIBF 1120 as Compared to bevacizumab in Combination Chemotherapy in Metastatic Colorectal Cancer
11. New Combination Locking Cap Designed to Protect Children and Teens From Prescription Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oregon , October 22, 2014 ... "Global Disposable Gloves Market (Product type, Form, End user, ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... global disposable gloves market. Based on key trends tracked, ... be valued at $7.9 billion by 2020, registering a ...
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
(Date:10/22/2014)... , Oct. 21, 2014   BioNano Genomics ... latest genomics research centers to purchase an ... the National Cancer Institute (NCI), NIH Intramural Sequencing ... Before Irys, obtaining a comprehensive view of a ... sequencing (NGS) does not deliver the scalability or ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
... more and are less likely ... to quit, ... Health shows the number of adult smokers in,the state is continuing to drop. ... has gone from 22.4,percent to a new low of 17 percent. Washington continues ...
... Continues to Decline; Strategic Business Unit Realignment, Completed; Clinical Update Provided ... ... Trial, BOCA RATON, Fla., Aug. 1 Nabi,Biopharmaceuticals ... recorded a net loss from continuing,operations of $5.3 million, or $0.09 per ...
Cached Medicine Technology:Adult Smoking Rate Continues Downward Trend 2Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 2Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 3Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 4Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 5Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 6Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 7Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 8Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 9Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 10Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 11Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 12Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 13
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/22/2014)... Dennis Thompson HealthDay ... U.S. health officials on Monday officially tightened guidelines for health ... no skin exposure and use of a respirator at all ... decided to issue the tougher rules after two Dallas nurses ... in the United States, Liberian national Thomas Eric Duncan. Nina ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... exposure causes genetic changes in breast cells , , THURSDAY, ... many plastic products used in households caused accelerated breast ... a condition that might predispose the animals to breast ... Butyl benzyl phthalate (BBP) is commonly used to soften ...
... occurrence in television shows and movies, but can watching it make ... Although research has shown ... there has been little direct neuroscientific support for this theory until ... Researchers at Columbia University Medical Centers Functional ...
... Program Sets Stage for Increased Visibility ... Among Shareholders and Investors, ... EMIS ) announced today that it has retained Adam,Friedman Associates, ... is a biopharmaceutical company that focuses on a,unique and improved ...
... Insmed Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... 5th Annual Global Follow-On Biologics,Conference on December 11, 2007 ... be held at the Hyatt Regency Hotel in Reston,Virginia, ... and will bring together corporate, regulatory, financial, and legal,experts ...
... SAN FRANCISCO, Calif., Dec. 6 Proteolix, Inc.,announced ... studies using,intravenous carfilzomib (PR-171) are to be presented ... Meeting in Atlanta, Georgia, December,8-10, 2007. Carfilzomib is ... for the treatment of multiple myeloma,lymphoma and solid ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) announced today details of ... chronic myelogenous leukemia,(CML) at the upcoming American Society of Hematology,s ... 8th - 11th, 2007 in,Atlanta, Georgia., , The schedule ... Date: ...
Cached Medicine News:Health News:Common Household Chemical Could Raise Breast Cancer Risk 2Health News:Common Household Chemical Could Raise Breast Cancer Risk 3Health News:This is your brain on violent media 2Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 2Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 3Health News:Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference 2Health News:Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 3Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 4
ELISA kit for detection of the cardiac marker Myoglobin. Kit features interchangeable reagents, E-Z Process performed at room temp, and results in less than 1 hour!...
... intended for the quantitative determination of prolactin ... in the diagnosis and treatment of disorders ... BioCheck Prolactin Quantitative Test is based on ... immunosorbent assay. The assay system utilized sheep ...
... assay is an immunometric ('sandwich') ... of Prolactin in human serum ... sample is bound by 2 ... epitopes. One antibody is attached ...
... ELISA Kit is enzyme immunoassay kit ... Prolactin (PRL) concentration in serum. Enzyme ... determination of many protein hormones in ... sensitive, reproducible, rapid and specific assay. ...
Medicine Products: